Global Smallpox Vaccine Market was worth of USD 63.46 Million in 2020 and it is expected to reach USD 78.58 Million by the end of 2027 with the CAGR of 3.1% during the Forecast Period.
Increasing contract manufacturing practices for developing smallpox vaccines and government plans for immunization and eradication of smallpox disease is fueling the global smallpox vaccine market. Global Smallpox Vaccine Market Size, Trends, Competitive, Historical & Forecast Analysis to 2021-2027.
Smallpox is a very infectious disease which is caused by the 2-virus called variolae major and variolae minor. This variolae virus belongs to the orthopoxvirus genus. Symptoms of smallpox are skin rashes, fever, vomiting, and ulcers. Smallpox is spread between people and through contaminated objects. Contaminated clothing and beds linens can also spread smallpox. The disease mainly survives in dry and cool conditions, and it spreads even faster in winter and early springs.
This infectious disease is only prevented through smallpox vaccine. The various types of vaccines that are used for the treatment of smallpox are Dryvax, ACAM2000, Calf Lymph, and MVA- BN. The smallpox vaccine is made up of live vaccinia virus which is a pox type virus. Edward Jenner introduced the modern smallpox vaccine in 1796. In 1959 WHO, also stared a program to eradicate smallpox. The 33rd World Health Assembly declared the world is free of this smallpox disease on May 8, 1980.
COVID-19 pandemic has a negative impact on the global smallpox vaccine market. This is due to the rising demand of the coronavirus vaccine and most of the key players were focused on manufacturing the vaccine for pandemic, the less transport and no labors also created a gap between the supply chains. Furthermore, the vaccines were generated to control the corona virus all over the world. According to world o meter, the confirmed cases of corona virus are 267,435,552 in which almost 5,287,411 died by 8th Dec’2021.
Global smallpox vaccine market is segmented on the basis of vaccine type, end user, and region and country level. Based on the vaccine type the global smallpox vaccine market is classified into first generation, second generation, and third generation. Based on the end user the global smallpox vaccine market is classified into hospitals, clinics, and others.
The regions covered in this global smallpox vaccines market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East ,GCC, (UAE, Saudi Arabia, Kuwait) Africa, etc.
September 30th, 2019: A new smallpox vaccine which is approved by the USAMRIID which is marketed by the brand name JYNNEOS, the product is developed by the Bavarian Nordic which is a live mom replication vaccine for the prevention of smallpox and monkey pox disease. JYNNEOS was developed as an alternative to current U.S. licensed ACAM2000 which is replicating smallpox vaccine. The peak neutralizing antibodies induced by JYNNEOS were shown to be twofold higher than those who are stimulated by ACAM2000, demonstrating a statistically superior immune response.
Increasing contract manufacturing practices for developing smallpox vaccine and government plans for immunization and eradication of smallpox disease is fueling the global smallpox vaccine market.
The factor that drives the global smallpox vaccine market is increasing in contract manufacturing practice for vaccine development. As there are no cases of smallpox recently there is no demand for the vaccine from the hospitals or government clinics. If needed there is always a manufacturing contract given to the manufacturing players for vaccine production which in turn can provide vaccines to hospitals. According to amnh.org, 300 million people have died by smallpox since 1900 but due to the vaccination campaign have put an end to the smallpox disease by 1977.
Another factor that boosts the global smallpox vaccine market is government programs for vaccination to eradicate smallpox disease globally. World Health Assembly started prospect of eradicating smallpox worldwide in 1950. The South Asian continent was mainly focused on the eradication program from late 1960 due to the high cases of smallpox. Due to the vaccination programs almost 80% vaccination got covered in each country.
According to the NCBI, United States and Soviet Union donated more than 150 million doses of vaccine and alone with this the world health assembly approved 2.4 million USD for eradication program. The restraining factor that hampered the growth of the global smallpox vaccine market was lack of knowledge for vaccination program and difficulties in manufacturing vaccine. The only opportunity that can raise the market is the increase in smallpox cases in future if found any.
The reason why the Asia pacific region is higher in cases of the smallpox diseases is large base of population, and initiative taken by government for eradicating smallpox disease. Indian government launched the National smallpox eradication program in 1962. According to the nytimes, almost 20,000 people died in the Indian state Bihar in one day in the year 1974. According to the umich.edu, almost 60 million primary vaccination and 440 million revaccination were performed. Also, in May 1970 the last case was found in India. Moreover, in the year 1977, the he International Commission for the Assessment of Eradication of Smallpox in India and finally certified that India was free from smallpox disease.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 63.46 Million|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2027:||USD 78.58 Million|
|Tables, Charts & Figures:||175|
|Smallpox Vaccine Manufacturer||Sanofi Pasteur Limited, Wyeth Laboratories Inc., Emergent BioSolutions Inc., Bavarian Nordic, SIGA Technologies, EpiVax|
|Segments Covered||By Vaccine Type, By End User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2023-24 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®